Mens Helene, Fjordside Lasse, Fonager Jannik, Gerstoft Jan
Rigshospitalet, Department of Infectious Diseases, 2100 Copenhagen, Denmark.
Viruses and Microbial Special Diagnostics, Statens Serum Institut, 2300 Copenhagen, Denmark.
Infect Dis Rep. 2022 Jun 22;14(4):501-504. doi: 10.3390/idr14040053.
HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1 combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase resistance. Here, we describe the occurrence of G118R in a HIV-1 subtype-B-positive individual with major compliance problems, detected while the patient was on dolutegravir-based cART. We speculate the pre-selection of M184I/V aided the occurrence of G118R in this case, and discuss the robustness of dolutegravir-based therapies.
HIV-1对整合酶抑制剂产生耐药性是HIV-1联合治疗成功的一个潜在威胁。G118R是一种罕见的耐药突变,可导致泛整合酶耐药。在此,我们描述了在一名存在严重依从性问题的HIV-1 B亚型阳性个体中检测到G118R的情况,该个体当时正在接受基于多替拉韦的抗逆转录病毒治疗。我们推测M184I/V的预先选择促成了该病例中G118R的出现,并讨论了基于多替拉韦疗法的稳健性。